Clinical trial
Study of Milnacipran for the Treatment of Fibromyalgia
NCT00314249 · Forest Laboratories, Industry · Completed
Key facts
| NCT number | NCT00314249 |
|---|---|
| Title | Study of Milnacipran for the Treatment of Fibromyalgia |
| Official title | A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia. |
| Lead sponsor | Forest Laboratories, Industry |
| Collaborators | Cypress Bioscience, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Fibromyalgia |
| Intervention type | Drug |
| Interventions | Placebo, Milnacipran 100mg |
| Enrollment | 1,025 |
| Start date | Apr 1, 2006 |
| Primary completion | Jun 1, 2008 |
| First posted | Apr 13, 2006 |
| Last update posted | Jan 20, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: